Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

378 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A phase 2 cancer chemoprevention biomarker trial of isoflavone G-2535 (genistein) in presurgical bladder cancer patients.
Messing E, Gee JR, Saltzstein DR, Kim K, diSant'Agnese A, Kolesar J, Harris L, Faerber A, Havighurst T, Young JM, Efros M, Getzenberg RH, Wheeler MA, Tangrea J, Parnes H, House M, Busby JE, Hohl R, Bailey H. Messing E, et al. Cancer Prev Res (Phila). 2012 Apr;5(4):621-30. doi: 10.1158/1940-6207.CAPR-11-0455. Epub 2012 Jan 31. Cancer Prev Res (Phila). 2012. PMID: 22293631 Free PMC article. Clinical Trial.
Prognostic markers for bladder cancer: International Consensus Panel on bladder tumor markers.
Habuchi T, Marberger M, Droller MJ, Hemstreet GP 3rd, Grossman HB, Schalken JA, Schmitz-Dräger BJ, Murphy WM, Bono AV, Goebell P, Getzenberg RH, Hautmann SH, Messing E, Fradet Y, Lokeshwar VB. Habuchi T, et al. Among authors: messing e. Urology. 2005 Dec;66(6 Suppl 1):64-74. doi: 10.1016/j.urology.2005.08.065. Urology. 2005. PMID: 16399416
Soy food frequency questionnaire does not correlate with baseline isoflavone levels in patients with bladder cancer.
Kolesar JM, Pomplun M, Havighurst T, Stublaski J, Wollmer B, Kim K, Tangrea JA, Parnes HL, House MG, Gee J, Messing E, Bailey HH. Kolesar JM, et al. Among authors: messing e. J Oncol Pharm Pract. 2015 Apr;21(2):128-31. doi: 10.1177/1078155214528552. Epub 2014 Mar 17. J Oncol Pharm Pract. 2015. PMID: 24642450 Free PMC article. Clinical Trial.
Phase Ib placebo-controlled, tissue biomarker trial of diindolylmethane (BR-DIMNG) in patients with prostate cancer who are undergoing prostatectomy.
Gee JR, Saltzstein DR, Messing E, Kim K, Kolesar J, Huang W, Havighurst TC, Harris L, Wollmer BW, Jarrard D, House M, Parnes H, Bailey HH. Gee JR, et al. Among authors: messing e. Eur J Cancer Prev. 2016 Jul;25(4):312-20. doi: 10.1097/CEJ.0000000000000189. Eur J Cancer Prev. 2016. PMID: 26313229 Clinical Trial.
Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markers.
Lokeshwar VB, Habuchi T, Grossman HB, Murphy WM, Hautmann SH, Hemstreet GP 3rd, Bono AV, Getzenberg RH, Goebell P, Schmitz-Dräger BJ, Schalken JA, Fradet Y, Marberger M, Messing E, Droller MJ. Lokeshwar VB, et al. Among authors: messing e. Urology. 2005 Dec;66(6 Suppl 1):35-63. doi: 10.1016/j.urology.2005.08.064. Urology. 2005. PMID: 16399415
Markers of detection.
Messing E. Messing E. Urol Oncol. 2007 Jul-Aug;25(4):344-7. doi: 10.1016/j.urolonc.2007.05.012. Urol Oncol. 2007. PMID: 17628306 Review.
378 results